Results 11 to 20 of about 1,071 (121)

Fully automated radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 with cyclotron produced gallium. [PDF]

EJNMMI Radiopharm Chem, 2023
Abstract Background Radiopharmaceuticals capable of targeting the fibroblast activation protein have become widely utilized in the research realm as well as show great promise to be commercialized; with [68Ga]Ga-FAPI-46 being one of the most widely utilized.
Rosenberg AJ, Cheung YY, Liu F, Sollert C, Peterson TE, Kropski JA.   +5 more
europepmc   +4 more sources

Safety of [⁶⁸Ga]Ga-FAPI-46 PET/CT including hemodynamic measurements and patient-reported outcomes in cancer patients. [PDF]

Clin Physiol Funct Imaging
Abstract Introduction Aim Fibroblast activation protein inhibitor (FAPI) has demonstrated promising oncological diagnostic performance. Although no adverse events (AEs) have been previously reported, a formal safety evaluation of FAPI PET/CT is lacking.
Bentestuen M, Sylvest C, Jensen SB, Soro LR, Knudsen A, Ladekarl M, Thorlacius-Ussing O, Fendler WP, Zacho HD.   +8 more
europepmc   +2 more sources

Fully-automated production of [⁶⁸Ga]Ga-FAPI-46 for clinical application. [PDF]

EJNMMI Radiopharm Chem, 2020
Abstract Background [68Ga]Ga-FAPI-46 is a promising radiopharmaceutical for in vivo detection of the fibroblast activation protein by positron emission tomography. Until now, the synthesis of [68Ga]Ga-FAPI-46 has been only performed manually.
Spreckelmeyer S, Balzer M, Poetzsch S, Brenner W.   +3 more
europepmc   +5 more sources

Automated Synthesis of [⁶⁸Ga]Ga-FAPI-46 on a Scintomics GRP Synthesizer. [PDF]

Pharmaceuticals (Basel), 2023
[68Ga]Ga-FAPI-46 is a radiolabelled fibroblast activation protein inhibitor that selectively binds to fibroblast activation protein (FAP), which is overexpressed by cancer-associated fibroblasts (CAFs) in the tumour microenvironment. In recent years, radiolabelled FAP inhibitors (FAPIs) are becoming increasingly important in cancer diagnostics and also
Plhak E, Pichler C, Dittmann-Schnabel B, Gößnitzer E, Aigner RM, Stanzel S, Kvaternik H.   +6 more
europepmc   +4 more sources

Repeatability of semi-quantitative [⁶⁸Ga]Ga-FAPI-46 PET/CT measurements in pancreatobiliary cancers: a test-retest study. [PDF]

Eur J Nucl Med Mol Imaging
Abstract Purpose Radiolabelled fibroblast activation protein inhibitors (FAPI) are promising molecular imaging tracers for the diagnosis and staging of pancreatobiliary cancer.
Henrar RB, Cysouw MCF, Palard-Novello X, Schwarte LA, Raijmakers PGHM, de Geus-Oei LF, Vahrmeijer AL, Kazemier G, Windhorst AD, Boellaard R, Yaqub M, Oprea-Lager DE, Swijnenburg RJ.   +12 more
europepmc   +6 more sources

[⁶⁸Ga]Ga-FAPI-46 PET enables non-invasive monitoring of hepatic fibrosis progression during TGF-β inhibition. [PDF]

Sci Rep
Kim Y, Jeong M, Choi GE, Kwon H, Yoon HJ, Jeong YJ, Park JY, Kang DY, Jun S.   +8 more
europepmc   +2 more sources

Bridging Research and Clinical Practice: Automated [⁶⁸Ga]Ga-FAPi-46 Synthesis and Quality Control for Oncological PET Imaging. [PDF]

Pharmaceuticals (Basel)
Background/Objectives: Fibroblast activation protein (FAP) has emerged as a promising target for oncologic molecular imaging due to its high expression in cancer-associated fibroblasts and low presence in healthy tissues. Among available FAP ligands, [68Ga]Ga-FAPi-46 has shown rapid tumor accumulation, low background uptake, and broad tumor ...
Santos CRP, Malavolta L, Mejia J, Lima Fuscaldi L, Yamaga LYI, Barboza MF.   +5 more
europepmc   +2 more sources

Microfluidic-based production of [⁶⁸Ga]Ga-FAPI-46 and [⁶⁸Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer. [PDF]

EJNMMI Radiopharm Chem, 2023
Abstract Background The demand for 68Ga-labeled radiotracers has significantly increased in the past decade, driven by the development of diversified imaging tracers, such as FAPI derivatives, PSMA-11, DOTA-TOC, and DOTA-TATE. These tracers have exhibited promising results in theranostic applications, fueling interest in
Mallapura H, Ovdiichuk O, Jussing E, Thuy TA, Piatkowski C, Tanguy L, Collet-Defossez C, Långström B, Halldin C, Nag S.   +9 more
europepmc   +5 more sources

A case of [⁶⁸Ga]Ga-FAPI-46-avid and [¹⁸F]F-FDG-negative COVID-19 pneumonia sequelae. [PDF]

Eur J Nucl Med Mol Imaging, 2022
A 72-year-old woman with COVID-19 respiratory syndrome symptoms underwent a chest CT scan (CT) for investigation. The CT detected a lung mass with no evidence of pneumonia (Fig. a); however, an RT-PCR nasopharyngeal swab (PCR) resulted positive for COVID-19 infection.
Telo S, Farolfi A, Castellucci P, Antonacci F, Solli P, Mosconi C, Fanti S, Agosti R, Morigi JJ, Nanni C.   +9 more
europepmc   +4 more sources

[68Ga]Ga-FAPI-46 PET/CT for Staging Suspected/Confirmed Lung Cancer: Results on the Surgical Cohort Within a Monocentric Prospective Trial. [PDF]

Pharmaceuticals (Basel)
Background/Objectives. To evaluate T&N-staging diagnostic performance of [68Ga]Ga-FAPI-46 PET/CT (FAPI) in a suspected/confirmed lung cancer surgical cohort. Methods: Patients were enrolled in a prospective monocentric trial (EudraCT: 2021-006570-23) to perform FAPI, in addition to conventional-staging-flow-chart (including [18F]F-FDG PET/CT-FDG ...
Zanoni L, Fortunati E, Cuzzani G, Malizia C, Lodi F, Cabitza VS, Brusa I, Emiliani S, Assenza M, Antonacci F, Giunchi F, Degiovanni A, Ferrari M, Natali F, Galasso T, Bandelli GP, Civollani S, Candoli P, D'Errico A, Solli P, Fanti S, Nanni C.   +21 more
europepmc   +5 more sources